CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential
Autor: | John L. Frater, Friederike Kreisel, Anjum Hassan, TuDung T. Nguyen, Mohammad Hussaini |
---|---|
Rok vydání: | 2016 |
Předmět: |
Pathology
medicine.medical_specialty medicine.medical_treatment CD4+ 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases medicine T-cell lymphoma CD20 Chemotherapy biology business.industry Germinal center Diffuse large B-cell lymphoma medicine.disease BCL6 Lymphoma Diagnostic Advances 030220 oncology & carcinogenesis biology.protein CD5 Lineage infidelity business 030215 immunology |
Zdroj: | World Journal of Methodology |
ISSN: | 2222-0682 |
DOI: | 10.5662/wjm.v6.i3.181 |
Popis: | CD4 expression is rare in diffuse large B-cell lymphoma (DLBCL), with 4 previously reported cases. Its significance is uncertain. We report five patients with CD4(+) DLBCL and one CD4(+) primary mediastinal large B-cell lymphoma. Cases were identified by searching the electronic database of the department; each was reviewed. Average age was 56 years. Neoplastic cells expressed CD20 (5/6 tested cases). BCL2/BCL6 expression were seen in 3/3 tested cases, suggesting a germinal center origin. Additionally, expression of T-cell antigens CD2 and CD5 was noted in 2/2 and CD7 in 1/1 tested case. CD3 was negative in all. Lymph nodes were commonly involved (67%). Patients received chemotherapy +/- radiation (6/6) and bone marrow transplant (2/6). Average survival was 44.2 mo. CD4 expression in DLBCL raises questions of lineage commitment. CD4(+) DLBCL is rare; care should be exercised not to diagnose these as T-cell lymphomas. A subset behaves aggressively. |
Databáze: | OpenAIRE |
Externí odkaz: |